HK Stock MarketDetailed Quotes
06855 ASCENTAGE-B
- 42.950
- -1.200-2.72%
Market Closed Dec 20 16:08 CST
13.54BMarket Cap-34.31P/E (TTM)
44.600High42.650Low2.02MVolume44.500Open44.150Pre Close87.75MTurnover0.64%Turnover RatioLossP/E (Static)315.21MShares48.85052wk High16.12P/B13.54BFloat Cap15.42052wk Low--Dividend TTM315.21MShs Float58.200Historical High--Dividend LFY4.42%Amplitude11.160Historical Low43.419Avg Price100Lot Size--Div YieldTTM--Div Yield LFY
About ASCENTAGE-B Company
Aspartic Pharma is a globally focused clinical-stage biotechnology company dedicated to developing novel therapies for cancer, hepatitis B virus, and age-related diseases. The company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. Aspiration Pharma has developed new products including eight drug candidates, including novel high-potency Bcl-2/Bcl-XL inhibitors, drug candidates targeting IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has conducted 28 phase I/II clinical trials to evaluate eight products in the US, Australia, and China to develop potential therapies as single drugs or combinations.
Company Profile
Symbol06855
Company NameASCENTAGE-B
ISINKYG0519B1023
Listing DateOct 28, 2019
Issue Price34.20
Shares Offered12.18M share(s)
FoundedNov 17, 2017
Registered AddressCayman Islands
Chairmandajun yang
Secretaryzhangqi wang
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeWalkers Corporate Limited Cayman Corporate Centre 27 Hospital Road George Town Grand Cayman KY1-9008 Cayman Islands
Head Office and Principal Place of BusinessFlat B, 17th Floor, United Centre, 95 Queensway, Admiralty, Hong Kong
Fiscal Year Ends12-31
Employees574
MarketHong Kong motherboard
Phone(86)51285557777
EmailIR@ascentage.com
Websitehttp://www.ascentage.cn
Business Yasheng Pharmaceutical Group is an investment holding company mainly engaged in the development of innovative microtherapies for cancer, hepatitis B virus and several age-related diseases. The company has a self-developed drug design platform targeting protein-protein interactions. The company's main products include the next-generation kinase inhibitor HQP1351, apoptosis targeting drugs APG-1252, APG2575, and APG-115. The company operates in the domestic market and overseas markets such as the US.
Company Executives
- Name
- Position
- Salary
- dajun yang
- Chairman of the Board, CEOs, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
- 4.78M
- shaomeng wang
- Non-executive Directors, Chairman of the Scientific Advisory Board
- 1.17M
- dazhong lv
- Non-executive Directors, Audit Committee Members
- 25.00K
- zhangqing ye
- Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members
- 502.00K
- wei ren
- Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members, Nomination Committee Members
- 502.00K
- David Sidransky
- Independent Non-Executive Director, Nomination Committee Members
- 510.00K
- Marina S. Bozilenko
- Independent Non-Executive Director
- --
- Debra Yu
- Independent Non-Executive Director
- --
- yifan di
- Chief Medical Officer
- --
- Raymond Jeffrey KMETZ
- Chief Commercial Officer
- --
- Thomas Joseph KNAPP
- Senior Vice President, General Counsel
- --
- zhangqi wang
- Authorized Representative, Company Secretary
- --
- gang zhu
- Chief Commercial Operations Officer
- --
Heat List
HK
Overall
Symbol
Price
% Chg
No Data
